At the end of the year, what are the pharmaceutical enterprises busy with?

[pharmaceutical network market analysis] it's only over a month before the end of 2019 At present, what are pharmaceutical enterprises busy with? From the disclosed information, in addition to busy year-end supply and consistency evaluation, many pharmaceutical enterprises have also invested a lot of thoughts in R & D layout, industrial layout, GMP certification, cost reduction and efficiency improvement Busy "supply" at the end of each year, the drug supply will be busy, and the suppliers are busy For example, since October, the pharmaceutical industry of Haici has been rushing to "speed up running", striving to achieve profits and taxes of 450 million yuan, a year-on-year increase of 30% It is reported that at present, on the basis of 16 varieties of products such as dizosin, dexmedetomidine hydrochloride and medloratadine in the first three quarters, 5 new varieties of products such as tegacyclin and parecoxib sodium will be added in the fourth quarter, realizing 21 varieties of products At present, many pharmaceutical enterprises are actively promoting consistency evaluation and gradually entering the harvest period According to incomplete statistics, within one week in October, 13 varieties (17 product specifications) have passed the consistency evaluation, involving pharmaceutical enterprises such as Shiyao group, Hengrui pharmaceutical, Yiling pharmaceutical and Shenzhen xinlitai pharmaceutical, and there are many pharmaceutical enterprises that have passed the consistency evaluation Busy with the influence of "industrial layout" on policies such as volume purchasing, the pattern of pharmaceutical market has changed, and pharmaceutical enterprises with advantages and strength are increasing their industrial layout For example, on October 28, GE Medical life sciences and kangfang pharmaceutical reached a cooperation, which will rapidly build GMP level antibody drug commercialization capacity, accelerate the listing process of kangfang pharmaceutical high-quality antibody new drugs, and help the industrialization development of biopharmaceutical industry It is reported that kangfang will further expand the layout, enrich the industrialization and commercialization of product lines, and build an international biomedical industrialization base in the future Busy "R & D layout" in the fierce market competition, as well as the support of pharmaceutical favorable policies, R & D innovation is more and more valued by pharmaceutical companies, and building a pharmaceutical R & D center has become a major trend For example, Haici is striving to build a API R & D center and expand its API R & D sub center in Nanjing In the fourth quarter, it plans to complete the pilot study of two projects, the finalization of drawings and decoration project approval of API Nanjing sub center Since the construction of Chenxin pharmaceutical R & D center started in July 2018, it is currently carried out in strict accordance with the plan and is expected to be completed and put into use in July next year After the official operation, the annual business income will be increased by 600 million yuan, and the annual profit and tax will be no less than 100 million yuan Busy with the "GMP certification" of the new product listing of pharmaceutical enterprises has always been a concern, after the end of the year, pharmaceutical enterprises are more busy in the "GMP certification" It is reported that at present, 13 API products in the new plant area of Xianju pharmaceutical have passed GMP on-site certification inspection, and the next 11 products will continue to undergo GMP certification inspection in batches In the fourth quarter of busy "cost reduction and efficiency improvement", with the gradual implementation of the expansion of volume procurement, the cost has become more and more important to consider due to the centralized quotation of multiple bid winning enterprises Under the background of rising cost, unsuccessful enterprises also need to consider how to control cost and increase efficiency It is reported that in the fourth quarter, Haici will continue to promote cost reduction and efficiency increase in the form of projects, and strive to reduce cost and save expenditure by 20 million yuan in the whole year And more pharmaceutical companies have been digging deep into the space of cost reduction and efficiency increase since this year For example, PLO pharmaceutical mentioned in the 2019 half year report that the company continued to promote various measures according to the business plans formulated at the beginning of the year, including digging deep into the space for cost reduction and efficiency increase, improving the construction of various systems, and building core competition barriers.